CN106509869A - Application of phosphatidylcholine combined with sodium bicarbonate in preparations of liver protecting food, health-care products or drugs - Google Patents
Application of phosphatidylcholine combined with sodium bicarbonate in preparations of liver protecting food, health-care products or drugs Download PDFInfo
- Publication number
- CN106509869A CN106509869A CN201610976510.1A CN201610976510A CN106509869A CN 106509869 A CN106509869 A CN 106509869A CN 201610976510 A CN201610976510 A CN 201610976510A CN 106509869 A CN106509869 A CN 106509869A
- Authority
- CN
- China
- Prior art keywords
- liver
- composition
- sodium bicarbonate
- phosphatid ylcholine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 title claims abstract description 40
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 title claims abstract description 39
- 210000004185 liver Anatomy 0.000 title claims abstract description 26
- 235000013305 food Nutrition 0.000 title claims description 16
- 239000003814 drug Substances 0.000 title claims description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 title abstract description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 title abstract description 11
- 229940079593 drug Drugs 0.000 title description 2
- 238000002360 preparation method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 208000010706 fatty liver disease Diseases 0.000 abstract description 13
- 208000004930 Fatty Liver Diseases 0.000 abstract description 12
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 12
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 12
- 102000004895 Lipoproteins Human genes 0.000 abstract description 9
- 108090001030 Lipoproteins Proteins 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 210000005229 liver cell Anatomy 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000012528 membrane Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000007423 decrease Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000003304 gavage Methods 0.000 description 8
- 231100000283 hepatitis Toxicity 0.000 description 8
- 208000006454 hepatitis Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000001095 phosphatidyl group Chemical group 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000020097 white wine Nutrition 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000004481 Choline Deficiency Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 208000021752 choline deficiency disease Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000007983 food acid Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention relates to a phosphatidylcholine and sodium bicarbonate composition. The effects of the composition are obviously superior to a single phosphatidylcholine. When liver cells are damaged, a transport function of lipoproteins decreases, so that the effect of the lipoproteins in transporting liver fat cannot be well played. An alkaline environment of human body is conducive to improving functional transport of human cell membranes and makes up decreased lipoprotein transport function in damaged liver cells to a certain extent, so that the phosphatidylcholine and sodium bicarbonate play a synergistic effect and provide a new choice for preventing and the treating fatty liver. Besides, the composition is free of toxic or side effects, suitable for a long-term use, and worthy of promotion and application.
Description
Technical field
The invention belongs to food, health products or medicine field.Specifically, the present invention relates to a kind of food for liver protecting
Product, health products or composite medicine.
Background technology
Liver is internal metabolism maincenter, therefore impact of the pathology of liver to health is great.Liver is general fatty 4%～
5%th, phosphatidase 2 %～3%, cholesterol 0.3%～0.5%, its component are more fixed, and when fatty excessive can form fat drop,
Put aside in liver, become fatty liver.Choline deficiency is a major reason for causing fatty liver.Fat is accumulated in liver and can be broken
Bad liver cell, easily causes cirrhosis, functional hepatic tissue is replaced by non-functional fibrous connective tissue, so as to serious shadow
A series of liver functions such as fat metabolism and removing toxic substances are rung, health is caused damage.
The high energy phosphatid ylcholine that phosphatid ylcholine can provide high dose, easily absorb, these phosphatid ylcholines
It is consistent with important endogenous phosphatide in chemical constitution.And phosphatid ylcholine is material necessary to liver synthesis lipoprotein,
Intrahepatic fat is then transported to outside liver with lipoprotein form.Lack phosphatide as lipoprotein biosynthesis block is easily caused fatty liver.Phosphatide
Phatidylcholine primarily enters liver cell, and is combined with liver plasma membrane and organelle film with complete molecule, in addition, courage can be secreted into
Juice.Therefore phosphatid ylcholine has following physiological function：Make impaired liver function and enzyme activity extensive by directly affecting membrane structure
It is multiple normal；Adjust the energy balance of liver；Promote hepatic tissue regeneration；Neutral fat and cholesterol are changed into into the shape of easy metabolism
Formula；Stable bile.
Human body is made up of 75,000,000 cells, and cell is just survived in our body fluid.Human body cell is innately in alkalescence
Operate in fluid environment.Cell can produce acid in operation, but these are weak acid, be organic acid, produce with acidic food
Acid it is different, they can be broken down into carbon dioxide and water, be discharged by lung.But, the acid produced by acidic food is stronger
Acid (sulfuric acid, phosphoric acid etc.), the health of human body can be threatened.There is sufficient scientific evidence to show, the big portion of body fluid of healthy human body
It is alkaline to divide, and pH value is all more than 7.0.Human body cell normal work is more beneficial under alkaline environment, is conducive to improving people
Somatic locomitivity, is conducive to improving the function transhipment of cell membrane.Meanwhile, under alkaline environment, phosphatidyl courage can be increased
Alkali absorption in vivo.
There is a good effect improving fatty liver, toxic liver injury etc. with phosphatid ylcholine in prior art, but suffer from
There is the liver cell qualitative change of fatty liver, patients with liver deficiency, liver plasma membrane is damaged, and makes the work(of phosphatidyl choline transport liver cell inner lipid
Can play well.
The content of the invention
It is an object of the invention to provide a kind of combination of the food, health products or medicine of more efficiently liver protecting
Thing.
The first object of the present invention, phosphatid ylcholine with reference to sodium acid carbonate prepare the food of liver protecting, health products or
Application in medicine.
The composition of a kind of food of liver protecting, health products or medicine involved by the second object of the present invention, mainly by
Phosphatid ylcholine and sodium acid carbonate composition.
The mass ratio of composition involved in the present invention is：Phosphatid ylcholine: sodium acid carbonate=5: 1～50: 1.
The more preferred mass ratio of composition involved in the present invention is：Phosphatid ylcholine: sodium acid carbonate=10: 1～30:
1。
The composition of the present invention is to be sufficiently mixed each component in mass ratio and be obtained.
The raw material or auxiliary material that above-mentioned composition is approved with food, health products and medicine makes popular acceptable food, guarantor
Strong product or medicine.Raw material such as vitamin, mineral matter, the material to hepatic injury with assistant protection function, protein and amino acid
Deng；Auxiliary material such as maltodextrin, FOS, milk powder, xylitol, magnesium stearate etc..
The formulation of above-mentioned composition can be the formulations such as powder, tablet, granule, capsule.Wherein, particularly preferred dose
Type is powder, granule, tablet.
Phosphatid ylcholine involved in the present invention and sodium bicarbonate composition, its effect are substantially better than single phosphatidyl courage
Alkali.When liver cell is damaged, the transport function of lipoprotein declines, it is impossible to play the fat in lipoprotein transhipment liver well.Human body
Be conducive to improving the function transhipment of human body cell film under alkaline environment, make up lipoprotein when liver cell is damaged to a certain extent
Transport function declines, therefore phosphatid ylcholine and sodium acid carbonate have played the effect of Synergistic, is prevention and treatment fatty liver
Have no toxic side effect there is provided new selection, and said composition, be adapted to Long-Time Service, be worthy of popularization.
Specific embodiment
The following examples of the present invention will be more specifically explained to the present invention, but the present invention is not limited only to these
Embodiment, same these embodiments also limit the present invention never in any form.
Phosphatid ylcholine purchase pleases to cure from Xi'an from Mai Ruier chemical technologies Co., Ltd of Shenzhen, sodium acid carbonate purchase
Medicine Science and Technology Ltd., the purchase of SD rats is from Beijing dimension tonneau China Experimental Animal Center.
The liver protecting preventive experiment of embodiment 1- phosphatid ylcholine+sodium bicarbonate composition
Animal used as test：SD rats, 40, male and female half and half, cleaning grade, animal are initially 6-8 week old, 120-150g, experiment
First three day is normally fed, and is randomly divided into 4 groups.
Experiment packet：First group：Blank group (10), second group：Hepatitis model group (10), the 3rd group：Hepatitis model
Composition (phosphatid ylcholine and sodium bicarbonate composition, in said composition, phosphatid ylcholine and the mass ratio of sodium acid carbonate are 50:
1) intervention group (10), the 4th group：Hepatitis model phosphatid ylcholine intervention group (10).In the 4th day, in addition to blank group its
Remaining each group every morning, the 3rd group of every afternoon, 5 points of gavages gave phosphatid ylcholine and carbon with 52 degree of white wine gavages (7mL/Kg)
Sour hydrogen composition of sodium, the 4th group of every afternoon, 5 points of gavages gave phosphatid ylcholine, blank group and hepatitis group gavage same volume
0.5%CMC-Na.
After successive administration 35 days, the serum glutamic pyruvic transminase (ALT) and glutamic-oxalacetic transaminease (AST) of each experimental group are detected.
Table 1：Packet situation and each group dosage
Table 2：Rat ALT and AST assay result (unit after being administered 35 days：U/L)
| Group | ALT content mean values | AST content mean values |
| Blank group | 45.64±6.11 | 163.17±17.68 |
| Hepatitis model group | 151.36±10.31 | 436.25±45.41 |
| Hepatitis model composition intervention group | 96.65±11.55 | 284.43±43.15 |
| Hepatitis model phosphatid ylcholine intervention group | 119.13±10.86 | 368.46±36.71 |
Embodiment 2- phosphatid ylcholine+sodium bicarbonate composition treatment fatty liver experiment
Animal used as test：SD rats, 40, male and female half and half, cleaning grade, animal are initially 6-8 week old, 120-150g, normally
Feed or high lipid food is fed.High lipid food feeding causes Models of Fatty Liver in 10 weeks.
Experiment packet：First group：Blank group (10), second group：Models of Fatty Liver group (10), the 3rd group：Fatty liver
Model composition (phosphatid ylcholine and sodium bicarbonate composition, the mass ratio of phosphatid ylcholine and sodium acid carbonate in said composition
For 50: 1) intervention group (10), the 4th group：Models of Fatty Liver phosphatid ylcholine intervention group (10).First three day is tested in experiment
Normally feeding under the conditions of room, starting normal diet to be fed except blank group in the 4th day, remaining each group feeds high lipid food, morning daily
Morning, the 3rd group of every afternoon, 5 points of gavages gave phosphatid ylcholine and sodium bicarbonate composition with 52 degree of white wine gavages (7mL/Kg),
4th group of every afternoon, 5 points of gavages gave the 0.5%CMC-Na of phosphatid ylcholine, blank group and hepatitis group gavage same volume.
After 4 weeks, the serum glutamic pyruvic transminase (ALT) and glutamic-oxalacetic transaminease (AST) of each experimental group are detected.
Table 1：Packet situation and each group dosage
Table 2：Rat ALT and AST assay result (units after being administered 10 weeks：U/L)
Experimental result and discussion：In terms of the glutamic-pyruvic transaminase for reducing alcoholic hepatitis and alcoholic fatty liver and causing,
Phosphatid ylcholine and phosphatid ylcholine have remarkable result with reference to sodium acid carbonate, and phosphatid ylcholine combines the effect of sodium acid carbonate
It is substantially better than phosphatid ylcholine.In a word, phosphatid ylcholine has functions that liver protecting with reference to sodium acid carbonate and is substantially better than list
Phosphatid ylcholine is used solely.
Embodiment 3- phosphatid ylcholine is used for preparing the formula of liver protecting food with reference to sodium acid carbonate：
Formula：The phosphatid ylcholine combines the Main Components of sodium bicarbonate composition：
Embodiment 4- phosphatid ylcholine is used for preparing the prescription of liver protecting medicine with reference to sodium acid carbonate：
Prescription：The phosphatid ylcholine combines the Main Components of sodium bicarbonate composition：
Claims (5)
1. a kind of composition of the food, health products or medicine for preparing liver protecting, it is characterised in that：The composition
Main Components are phosphatid ylcholine and sodium acid carbonate.
2. composition according to claim 1, it is characterised in that：The mass ratio of the phosphatid ylcholine and sodium acid carbonate
For：5: 1～50: 1.
3. composition according to claim 1, it is characterised in that：The mass ratio of the phosphatid ylcholine and sodium acid carbonate
For：10: 1～30: 1.
4. application of the composition according to any claim in claim 1-3 in the medicine for preparing liver protecting.
5. the composition according to any claim in claim 1-3 is in the food of liver protecting, health products are prepared
Application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610976510.1A CN106509869A (en) | 2016-11-07 | 2016-11-07 | Application of phosphatidylcholine combined with sodium bicarbonate in preparations of liver protecting food, health-care products or drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610976510.1A CN106509869A (en) | 2016-11-07 | 2016-11-07 | Application of phosphatidylcholine combined with sodium bicarbonate in preparations of liver protecting food, health-care products or drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106509869A true CN106509869A (en) | 2017-03-22 |
Family
ID=58349535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610976510.1A Pending CN106509869A (en) | 2016-11-07 | 2016-11-07 | Application of phosphatidylcholine combined with sodium bicarbonate in preparations of liver protecting food, health-care products or drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106509869A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032497A (en) * | 2006-03-08 | 2007-09-12 | 苑立超 | Polyenylphosphatidylcholine freeze - dried powder injection for injecting and the preparing method thereof |
| CN101513390A (en) * | 2009-03-24 | 2009-08-26 | 沈阳药科大学 | Hydrochloric acid boanmycin liposomes and preparation method thereof |
| CN101569606A (en) * | 2009-06-09 | 2009-11-04 | 沈阳药科大学 | Curcumol liposome and preparation method thereof |
-
2016
- 2016-11-07 CN CN201610976510.1A patent/CN106509869A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032497A (en) * | 2006-03-08 | 2007-09-12 | 苑立超 | Polyenylphosphatidylcholine freeze - dried powder injection for injecting and the preparing method thereof |
| CN101513390A (en) * | 2009-03-24 | 2009-08-26 | 沈阳药科大学 | Hydrochloric acid boanmycin liposomes and preparation method thereof |
| CN101569606A (en) * | 2009-06-09 | 2009-11-04 | 沈阳药科大学 | Curcumol liposome and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11547736B2 (en) | Sauvignon blanc grape seed products for nonalcoholic fatty liver disease | |
| EP1827136B1 (en) | Formulation for oral administration having a health-promoting effect on the cardiovascular system | |
| KR20170099539A (en) | Sedum composition promoting antioxidant and alcohol oxidation | |
| EP3165221B1 (en) | Blood-fat reducing composition and application thereof | |
| US20170007630A1 (en) | Composition and method of delivery of l-arabinose and select compounds | |
| WO2007014379A2 (en) | A lipidic extract from lepidium meynii and its effect on the libido | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN106509869A (en) | Application of phosphatidylcholine combined with sodium bicarbonate in preparations of liver protecting food, health-care products or drugs | |
| JP5961034B2 (en) | Stabilization method | |
| JP2011088939A (en) | Internal pharmaceutical preparation | |
| JP2007031302A (en) | Adiponectin production accelerator and metabolic syndrome preventive | |
| TWI731242B (en) | Composition for alcohol detoxification | |
| KR101393607B1 (en) | Composition containing fermented rice bran for the prevention and treatment of non-alcoholic fatty liver | |
| CN106349318A (en) | Application of pentacyclic triterpene compounds to preparation of medicine for treating adiposis | |
| KR20110132887A (en) | Composition for improving hepatic, stomachic function and curing hangover | |
| TWI441643B (en) | Composition for adjusting blood lipid and cardiovascular protection | |
| CN108686199B (en) | Liver protecting composition | |
| JP4850402B2 (en) | Oral preparation | |
| WO2018062354A1 (en) | Intestinal microbiota improving agent and intestinal microbiota improving composition that include eggshell membrane–containing powder | |
| CN108159201A (en) | A kind of product for adjusting Hyperlipemia population intestinal flora and preparation method and application | |
| CN102793740B (en) | Nutrient particles with auxiliary protecting function on chemical liver injury | |
| US11253531B2 (en) | Lipid supplements for reducing nerve action potentials | |
| CN106563038B (en) | Taurine and fat-soluble tea polyphenol compound composition, preparation method and application thereof | |
| Ohadoma | Comparative analysis of hepatoprotective effect of ethanol extracts of Gongronema latifolium and Alternanthera dentate leaves in rats | |
| RU2319497C2 (en) | Agent for enhancing body resistance against viral and virus-induced diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170322 |